losartan and Uremia
losartan has been researched along with Uremia in 14 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 9.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 5.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| " Transcriptional screening of ACE-overexpressing monocytes revealed noticeably increased expression of Angiotensin II receptors and adhesion- as well as atherosclerosis-related ICAM-1 and VCAM1." | 3.80 | Uremic conditions drive human monocytes to pro-atherogenic differentiation via an angiotensin-dependent mechanism. ( Fiedler, R; Girndt, M; Seibert, E; Trojanowicz, B; Ulrich, C, 2014) |
| " Losartan significantly attenuated the expression of TGF-β1 and Snail, and decreased kidney fibrosis induced by IS and PCS in vivo." | 3.78 | Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. ( Chang, SC; Sun, CY; Wu, MS, 2012) |
| "Uremia was induced in apoE-/- mice by 5/6 nephrectomy (NX)." | 1.34 | Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. ( Binder, CJ; Bro, S; Nielsen, LB; Olgaard, K; Witztum, JL, 2007) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
Research
Studies (14)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kovács, ZZA | 1 |
| Szűcs, G | 1 |
| Freiwan, M | 1 |
| Kovács, MG | 1 |
| Márványkövi, FM | 1 |
| Dinh, H | 1 |
| Siska, A | 1 |
| Farkas, K | 1 |
| Kovács, F | 1 |
| Kriston, A | 1 |
| Horváth, P | 1 |
| Kővári, B | 1 |
| Cserni, BG | 1 |
| Cserni, G | 1 |
| Földesi, I | 1 |
| Csont, T | 1 |
| Sárközy, M | 1 |
| Wei, S | 1 |
| Sun, J | 1 |
| Li, Y | 1 |
| Xu, K | 1 |
| Wang, M | 1 |
| Zhang, Y | 1 |
| Uchiyama, H | 1 |
| Tsujimoto, M | 2 |
| Shimada, N | 1 |
| Tsutsui, K | 1 |
| Nitta, A | 1 |
| Yoshida, T | 1 |
| Furukubo, T | 2 |
| Izumi, S | 2 |
| Yamakawa, T | 2 |
| Tachiki, H | 1 |
| Minegaki, T | 1 |
| Nishiguchi, K | 2 |
| Trojanowicz, B | 1 |
| Ulrich, C | 1 |
| Seibert, E | 1 |
| Fiedler, R | 1 |
| Girndt, M | 1 |
| Higuchi, K | 1 |
| Shima, D | 1 |
| Yokota, H | 1 |
| Otagiri, M | 1 |
| Hirata, S | 1 |
| Takara, K | 1 |
| Reyes, M | 1 |
| Benet, LZ | 1 |
| Sun, CY | 1 |
| Chang, SC | 1 |
| Wu, MS | 1 |
| Wolf, SC | 1 |
| Sauter, G | 1 |
| Risler, T | 1 |
| Brehm, BR | 1 |
| Lavoie, P | 1 |
| Robitaille, G | 1 |
| Agharazii, M | 2 |
| Ledbetter, S | 1 |
| Lebel, M | 3 |
| Larivière, R | 3 |
| Rodrigue, ME | 1 |
| Bro, S | 1 |
| Binder, CJ | 1 |
| Witztum, JL | 1 |
| Olgaard, K | 1 |
| Nielsen, LB | 1 |
| Cohen, LS | 1 |
| Friedman, EA | 1 |
| Cice, G | 1 |
| Ferrara, L | 1 |
| Tagliamonte, E | 1 |
| Russo, PE | 1 |
| Di Benedetto, A | 1 |
| Iacono, A | 1 |
| Dumont, Y | 1 |
| D'Amours, M | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Monocytes Adhesion and Vascular Lesions in Vascular Access Success or Failure in Uremic Patients[NCT03231410] | 30 participants (Anticipated) | Observational | 2017-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trials
1 trial available for losartan and Uremia
| Article | Year |
|---|---|
[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Other Studies
13 other studies available for losartan and Uremia
| Article | Year |
|---|---|
Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Antihypertensive Agents; Cardiomyopathie | 2021 |
Losartan Attenuates Atherosclerosis in Uremic Mice by Regulating Treg/Th17 Balance via Mediating PTEN/PI3K/Akt Pathway.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Interleukin-10; Interleukin-17; Interleukin-6; Los | 2022 |
Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells.
Topics: Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2018 |
Uremic conditions drive human monocytes to pro-atherogenic differentiation via an angiotensin-dependent mechanism.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2014 |
Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro.
Topics: Angiotensin II Type 1 Receptor Blockers; Aryl Hydrocarbon Hydroxylases; Cresols; Cytochrome P-450 CY | 2010 |
Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.
Topics: Animals; Area Under Curve; Biopharmaceutics; Chromatography, Liquid; Estrone; Hepatocytes; Humans; K | 2011 |
Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition.
Topics: Angiotensinogen; Animals; Cresols; Epithelial-Mesenchymal Transition; Fibrosis; Gene Expression Regu | 2012 |
Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2005 |
Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta, Thoracic; Blood Pressure; Blott | 2005 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodi | 2007 |
Losartan-induced azotemia in a diabetic recipient of a kidney transplant.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1996 |
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Endothelin-1; En | 2001 |